133 related articles for article (PubMed ID: 35637403)
21. Establishment and characterization of NCC-DFSP3-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line.
Yoshimatsu Y; Noguchi R; Tsuchiya R; Sei A; Nakagawa M; Yoshida A; Kawai A; Kondo T
Hum Cell; 2020 Jul; 33(3):894-903. PubMed ID: 32356243
[TBL] [Abstract][Full Text] [Related]
22. Establishment and characterization of NCC-MFS3-C1: a novel patient-derived cell line of myxofibrosarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Sin Y; Ono T; Sei A; Takeshita F; Sugaya J; Iwata S; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2021 Jul; 34(4):1266-1273. PubMed ID: 33990915
[TBL] [Abstract][Full Text] [Related]
23. Establishment and characterization of a novel cell line, NCC-DDLPS2-C1, derived from a patient with dedifferentiated liposarcoma.
Noguchi R; Yoshimatsu Y; Ono T; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
Hum Cell; 2021 May; 34(3):990-997. PubMed ID: 33555519
[TBL] [Abstract][Full Text] [Related]
24. Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.
de Graaff MA; Yu JS; Beird HC; Ingram DR; Nguyen T; Juehui Liu J; Bolshakov S; Szuhai K; Åman P; Torres KE; Lev D; Nielsen TO; Bovée JV; Lazar AJ; Somaiah N
Lab Invest; 2016 Aug; 96(8):885-94. PubMed ID: 27270875
[TBL] [Abstract][Full Text] [Related]
25. Establishment and characterization of a novel alveolar rhabdomyosarcoma cell line, NCC-aRMS1-C1.
Sin Y; Yoshimatsu Y; Noguchi R; Tsuchiya R; Sei A; Ono T; Toki S; Kobayashi E; Arakawa A; Sugiyama M; Yoshida A; Kawai A; Kondo T
Hum Cell; 2020 Oct; 33(4):1311-1320. PubMed ID: 32715445
[TBL] [Abstract][Full Text] [Related]
26. Expression of CTAG1B clone EPR13780 versus
Abdelaziz MM; Tayel HY; Abdel-Bary A; Badawy OM
J Histotechnol; 2022 Jun; 45(2):56-65. PubMed ID: 34845972
[TBL] [Abstract][Full Text] [Related]
27. Establishment and characterization of NCC-ssRMS2-C1: a novel patient-derived cell line of spindle cell/sclerosing rhabdomyosarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Sin Y; Ono T; Sei A; Takeshita F; Sugaya J; Nakatani F; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2021 Sep; 34(5):1569-1578. PubMed ID: 34164773
[TBL] [Abstract][Full Text] [Related]
28. Establishment and characterization of a novel cell line, NCC-MFS1-C1, derived from a patient with myxofibrosarcoma.
Kito F; Oyama R; Sakumoto M; Shiozawa K; Qiao Z; Toki S; Yoshida A; Kawai A; Kondo T
Hum Cell; 2019 Apr; 32(2):214-222. PubMed ID: 30737712
[TBL] [Abstract][Full Text] [Related]
29. The FUS::DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma.
Zullow HJ; Sankar A; Ingram DR; Samé Guerra DD; D'Avino AR; Collings CK; Lazcano R; Wang WL; Liang Y; Qi J; Lazar AJ; Kadoch C
Mol Cell; 2022 May; 82(9):1737-1750.e8. PubMed ID: 35390276
[TBL] [Abstract][Full Text] [Related]
30. Establishment and characterization of the NCC-GCTB4-C1 cell line: a novel patient-derived cell line from giant cell tumor of bone.
Ono T; Noguchi R; Yoshimatsu Y; Tsuchiya R; Sin Y; Nakagawa R; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
Hum Cell; 2022 Jan; 35(1):392-399. PubMed ID: 34731453
[TBL] [Abstract][Full Text] [Related]
31. DNA damage-inducible transcript 3 immunohistochemistry is highly sensitive for the diagnosis of myxoid liposarcoma but care is required in interpreting the significance of focal expression.
Vargas AC; Chan NL; Wong DD; Zaborowski M; Fuchs TL; Ahadi M; Clarkson A; Sioson L; Sheen A; Maclean F; Bonar F; Cheah A; Jones M; Chou A; Gill AJ
Histopathology; 2021 Jul; 79(1):106-116. PubMed ID: 33465826
[TBL] [Abstract][Full Text] [Related]
32. Establishment and characterization of NCC-MFS6-C1: a novel patient-derived cell line of myxofibrosarcoma.
Yoshimatsu Y; Noguchi R; Sin Y; Tsuchiya R; Ono T; Akiyama T; Sato C; Kobayashi E; Kojima N; Yoshida A; Kawai A; Kondo T
Hum Cell; 2022 Nov; 35(6):1993-2001. PubMed ID: 35947340
[TBL] [Abstract][Full Text] [Related]
33. The utility of fluorescence in situ hybridization (FISH) in determining DNA damage-inducible transcript 3 (DDIT3) amplification in dedifferentiated liposarcomas - an important diagnostic pitfall.
Kuczkiewicz-Siemion O; Wiśniewski P; Dansonka-Mieszkowska A; Grabowska-Kierył M; Olszewska K; Goryń T; Prochorec-Sobieszek M; Rutkowski P; Szumera-Ciećkiewicz A
Pathol Res Pract; 2021 Sep; 225():153555. PubMed ID: 34325315
[TBL] [Abstract][Full Text] [Related]
34. Establishment and characterization of NCC-SS4-C1: a novel patient-derived cell line of synovial sarcoma.
Tsuchiya R; Yoshimatsu Y; Noguchi R; Ono T; Sei A; Takeshita F; Sugaya J; Iwata S; Yoshida A; Ohtori S; Kawai A; Kondo T
Hum Cell; 2021 May; 34(3):998-1007. PubMed ID: 33611700
[TBL] [Abstract][Full Text] [Related]
35. Establishment and characterization of patient-derived cancer models of malignant peripheral nerve sheath tumors.
Oyama R; Kito F; Takahashi M; Hattori E; Noguchi R; Takai Y; Sakumoto M; Qiao Z; Toki S; Sugawara M; Tanzawa Y; Kobayashi E; Nakatani F; Iwata S; Yoshida A; Kawai A; Kondo T
Cancer Cell Int; 2020; 20():58. PubMed ID: 32099531
[TBL] [Abstract][Full Text] [Related]
36. Establishment and characterization of NCC-DFSP5-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line.
Ono T; Noguchi R; Osaki J; Akiyama T; Adachi Y; Kojima N; Toda Y; Fukushima S; Yoshimatsu Y; Yoshida A; Kawai A; Kondo T
Hum Cell; 2024 May; 37(3):854-864. PubMed ID: 38372888
[TBL] [Abstract][Full Text] [Related]
37. Establishment and characterization of NCC-SS5-C1: a novel patient-derived cell line of synovial sarcoma.
Yoshimatsu Y; Noguchi R; Sin Y; Tsuchiya R; Ono T; Akiyama T; Sugaya J; Kojima N; Yoshida A; Kawai A; Kondo T
Hum Cell; 2022 Jul; 35(4):1290-1297. PubMed ID: 35655041
[TBL] [Abstract][Full Text] [Related]
38. Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma.
Noguchi R; Yoshimatsu Y; Ono T; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
Hum Cell; 2021 Jan; 34(1):246-253. PubMed ID: 32870449
[TBL] [Abstract][Full Text] [Related]
39. Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.
Göransson M; Elias E; Ståhlberg A; Olofsson A; Andersson C; Aman P
Int J Cancer; 2005 Jul; 115(4):556-60. PubMed ID: 15688424
[TBL] [Abstract][Full Text] [Related]
40. Establishment and characterization of NCC-LMS3-C1: a novel patient-derived cell line of leiomyosarcoma.
Yoshimatsu Y; Noguchi R; Osaki J; Sin Y; Tsuchiya R; Ono T; Akiyama T; Adachi Y; Tanzawa Y; Yoshida A; Kawai A; Kondo T
Hum Cell; 2024 Jan; 37(1):337-344. PubMed ID: 37907774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
